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INTRODUCTION
Arrhythmogenic right ventricular cardiomyopathy/
dysplasia (ARVC/D) is a myocardial disease in which
myocardium of the right ventricular free wall is partially
or almost entirely replaced by fatty or fibro-fatty tissue
(1-3).  The process begins at epicardium and it spreads
towards the endocardium. The anterior right ventricular
outflow tract, the apex, and the inferior-posterior wall–
the so-called “triangle of dysplasia”– are primarily in-
volved (4).  The degenerative process may be segmen-
tal or diffuse; on post mortem examination degenera-
tion results to affect the left ventricle in about 50% of
cases and to involve the septum only in 20% (3). Clini-
cal manifestations of the disease mostly occur between
the second and fourth decade of life; they include struc-
tural and functional abnormalities of the right ventricle,
electrocardiographic depolarization/repolarization changes
and arrhythmias of right ventricular origin (5). Ventricu-
lar tachycardias are thought to be due to re-entry be-
tween the abnormal and normal areas of the right ven-
tricular myocardium. 
ARVC is a progressive heart muscle disease with dif-
ferent clinico-pathological patterns: a) “silent” car-
diomyopathic abnormalities localized to the right ventri-
cle in asymptomatic victims of sudden death; b) “overt”
disease characterized by segmental or global right ven-
tricular structural changes, often associated with histo-
logical evidence of left ventricular involvement and un-
derlying symptomatic ventricular arrhythmias; c) “end-
stage” biventricular cardiomyopathy mimicking dilated
cardiomyopathy, which leads to progressive heart fail-
ure and may require heart transplantation (6).
A scoring system to establish diagnosis of ARVC has
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been developed on the basis of the presence of major
and minor criteria encompassing structural, histologi-
cal, electrocardiographic, arrhythmic and genetic fea-
tures of the disease (7). Drug treatment is warranted in
patients with palpitations, syncope or documented sus-
tained ventricular arrhythmias. Anti-arrhythmic drugs
are used to suppress atrial and ventricular arrhythmias.
Clinical investigation aims at identifying subjects at risk
of complications in order to provide them proper treat-
ment.
Prevalence and incidence of ARVC are still ill-estab-
lished. Ten years ago, we estimated that prevalence rate
of ARVC in the Veneto region of Italy might be about
1:1500 (8); however prevalence could be higher, be-
cause of many non-diagnosed or misdiagnosed cases.
It was reported that in Italy, between 12.5 and 25% of
sudden death events in young non-athletes and young
athletes under the age of 35 years were caused by un-
diagnosed ARVC (9). 
Two international registries, in Europe and USA, are
presently on the way, aiming at determining clinical,
pathological and genetic features of ARVC, at validating
diagnostic criteria and at defining strategies for disease
management and sudden death prevention (10-12).
Familial occurrence is common, and in ~50% of
cases evidence has been found for autosomal domi-
nant inheritance with variable penetrance (13). Reces-
sive forms are also described, although in association
with cutaneous disorders (14). Since the identification
of the first ARVC locus in 1994 (8), ten loci were de-
tected, but only five disease genes have been identi-
fied so far (15-19).
Recessive forms
The first ARVC gene was identified in a rare syn-
drome, characterized by arrhythmogenic right ventricu-
lar cardiomyopathy associated with palmoplantar kera-
toderma and peculiar woolly hairs, inherited as autoso-
mal recessive trait.
This syndrome was called “Naxos syndrome”, be-
cause of a peculiar concentration of cases in the Greek
island of Naxos. Clinical features of the disease were
first described by Protonotarios in 1986 (14); ten years
later, the syndrome was recognized as a distinct human
disease and as a variant of ARVD (OMIM 601214).
The pattern of disease stereotyped in all cases. At
birth woolly hair is present. At that time or shortly after,
palmar erythema occurs, and when the infants start to
use their hands keratoderma develops. Later, when they
start to ambulate, plantar erythema occurs, followed by
keratoderma and producing the typical pattern. 
Cardiac abnormality presents later. All patients pre-
sent electrocardiographic and/ or echocardiographic
abnormalities fulfilling criteria of ARVC. The sympto-
matic presentation is usually with syncope and/or sus-
tained ventricular tachycardia during adolescence with
a peak in young adulthood (20).
The presence of a visible defect in epidermal cells
suggested that cardiac defect could be closely linked to
a locus to which keratin genes were mapped. Indeed,
DNA markers of the chromosomal region 17 did show
positive linkage with the disease (21). Shortly later, mu-
tation screening of plakoglobin gene, closely linked to
keratin genes, succeeded in detecting in Naxos patients
a two-nucleotide deletion (Pk2157del2TG) producing a
frameshift which alters five amino acids and produces a
stop codon (15). A genotype-phenotype correlation
study, performed on 26 subjects, showed that the re-
cessive trait is fully penetrant by adolescence (20). A
minority of heterozygous carriers presented few pheno-
typic features consisting of woolly hair and minor elec-
trocardiographic/echocardiographic changes, not ful-
filling the criteria for ARVD. 
Plakoglobin is a key component of desmosomes and
adherens junctions. It is involved in tight adhesions of
many  cell  types,  cardiomyocytes  included  and  is
thought to serve as a linker molecule between the inner
and outer portions of the desmosomal plaque by bind-
ing tightly to the cytoplasmatic domain of cadherins.
The  adhesive  function  of  plakoglobin  is  mediated
through its interaction with other desmosomal and cy-
tosolic proteins; highly conserved armadillo repeats,
which form the central domain of plakoglobin, facilitate
the association between plakoglobin and these mole-
cules (22, 23). Plakoglobin has also been shown to di-
rectly signal structural changes in adherens junctions to
the nucleus (24, 25). Normal functioning of cell-cell
junctions is of utmost importance in myocardium and
skin particularly of palms and soles, tissues that experi-
ence constant mechanical stress. Intercellular junctions
not only maintain tissue integrity but also integrate me-
chanical and signaling pathways. Defects in linkingRampazzo
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sites of plakoglobin might disturb the contiguous cell-
cell adhesion and tissue integrity in skin and heart par-
ticularly when increased mechanical stress is applied
on the tissue. This mechanism has been fostered in
plakoglobin-null  mice  myocardium  presenting  de-
creased compliance and ventricular rupture under in-
creased mechanical stress (26). 
More recently, Alcalai et al identified a missense mu-
tation in the C-terminal of desmoplakin in one Arabic
family with recessive ARVC, woolly hair and a pem-
phigous-like skin disorders (27). Desmoplakin, together
with plakoglobin, is a constituent of the desmosomal
plaque, anchoring intermediate filaments to the plasma
membrane and forming a scaffold that is essential for
maintaining tissue integrity. 
Interestingly, in two additional Arabic families, clini-
cally affected with Naxos disease, mutations in genes
encoding plakoglobin, desmoplakin, plakophilin 1, 2,
and 4, types I and II keratin, desmoyokin and desmo-
collins/desmogleins have been excluded, thus suggest-
ing additional genetic heterogeneity in this cardiocuta-
neous syndrome (28).
Dominant forms
The first ARVC gene identified in a dominant form
was cardiac ryanodine receptor involved in ARVD2 (16).
ARVD2 shows fibro-fatty substitution of the myocardial
tissue, though much less pronounced than in the typical
ARVCs. However, the distinctive feature of this form is
the presence of polymorphic, effort-induced arrhyth-
mias.
After restriction of the critical region on chromosome
1q42-q43 and the unsuccessful mutation screening of
different  genes  mapped  to  the  critical  interval,
causative mutations were finally detected in the gene
encoding the monomer of the cardiac ryanodine recep-
tor (RyR2) (16). hRYR2 is one of the largest human
genes (105 exons); it encodes a 565Kda protein. The
homo-tetrameric structure known as cardiac ryanodine
receptor plays a pivotal role in intracellular calcium
homeostasis and excitation-contraction coupling in
cardiomyocytes. 
Stimulation  of  voltage-sensitive  L-type  calcium
channels (dihydropyridine receptors) on the outer my-
ocardial  cell  membrane  allows  the  entry  of  small
amounts of calcium ions, which in turn activate release
of larger amounts of calcium from the sarcoplasmic
reticulum lumen into the cytoplasm via RyR2. This is
sufficient to initiate myocardial contraction. Thus, RYR2
channels serve to couple the excitation of myocardial
cells to their actin/myosin contractile apparatus by a
mechanism involving a calcium-induced calcium re-
lease (29, 30).
All RYR2 missense mutations detected in ARVD2 pa-
tients resulted in substitution involving amino acids
highly conserved through evolution in domains of the
protein which are critical for the regulation of the calci-
um channel (31). 
Up to present, mutations in the human RYR2 gene
have been associated with three inherited cardiac dis-
eases: arrhythmogenic right ventricular cardiomyopa-
thy  type  2  (ARVD2;  OMIM  600996)  (16,  32),  cate-
cholaminergic  polymorphic  ventricular  tachycardia
(CPVT; OMIM 604772) (33, 34) and familial polymorphic
ventricular tachycardia (FPVT); OMIM 604772) (35, 36).
All these diseases are characterized by effort-induced
polymorphic ventricular arrhythmias and a risk of sud-
den death. Moreover, putative pathogenic mutations in
RYR2 have been reported in 20 of 240 patients with
long-QT syndrome (37). All RYR2 mutations described
to date show clustering in three specific domains: the
N-terminal amino-acid residues 176-433, the centrally
located  residues  2246-2504,  and  the  C-terminal
residues 3778-4959.
The finding of RYR2 mutations in both ARVD2 and
CPVT patients raised the question of the possible exis-
tence of a single genetic defect whose different pheno-
types might be simply due to variable expression and
incomplete penetrance. Interestingly, a 17 year-old boy,
who died suddenly and at postmortem showed fibrofat-
ty replacement in the right ventricular free wall consis-
tent with ARVC, resulted as carrying a missense RYR2
mutation (A77V) (38). His mother and sister, carrying the
same RYR2 mutation, showed effort-induced polymor-
phic ventricular tachycardia in the setting of normal
echocardiogram consistent with CPVT. The observation
of both ARVD2 and CPVT in the same family suggests
that the two entities might correspond to different de-
grees of phenotypic expression of the same disease.
Both the ARVD2- and CPVT-RyR2 missense muta-
tions (16, 33) would alter the ability of the calcium chan-
nel to remain closed and thus, intense adrenergic stim-Genetics of ARVC
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ulation due to emotional or physical stress would lead
to calcium overload, thus triggering severe arrhythmias. 
Leaky RyR channels might release SR Ca2+ during
the resting phase of the cardiac cycle (diastole), result-
ing in membrane depolarizations that occur after repo-
larization of the previous action potential (delayed after-
depolarizations, DADs) (39). In support of this hypothe-
sis it has recently been reported that DADs are known to
trigger premature ventricular contractions which can
initiate fatal cardiac arrhythmias (40).
Beta-blockers therapy proved to be effective in pre-
venting fatal arrhythmias in several ARVD2 and CPVT
patients (16,33). This may be explained by the fact that
the rapid enhancement of cardiac output during exer-
cise or sudden stress is based on the ß-AR cascade
(41). Therefore, blockage of ß-AR signaling would result
in improved cardiac contractility, as shown in human
heart failure (42).
Several functional studies on RyR2 mutations have
been reported so far. The common finding, both in
CPVT- and ARVD2-associated mutations (43-46) is an
increased Ca2+ release after stimulation.
Functional role of mutations R176Q, L433P, N2386I
and T2504M, previously detected in ARVD2 patients
and reported by Tiso et al 2001, was recently investigat-
ed (46). RyR2 mutants N2386I and R176Q/T2504M ex-
hibited enhanced sensitivity to caffeine activation and
increased Ca2+ release, in agreement with the current
hypothesis that defective RyR2 cause Ca2+ leak. On the
contrary, RyR2 L433P mutation showed reduced re-
sponse to caffeine activation. This mutation might be in-
terpreted as a “loss-of-function”. Therefore, RyR2 mu-
tations might be either “gain-of-function” or “loss-of-
function”, thus suggesting heterogeneity in functional
consequences of RyR2 mutations.
The first disease gene linked to autosomal dominant
ARVC showing the typical right ventricular phenotype
was desmoplakin (17). DNA sequencing of all DSP ex-
ons in the index case of the investigated family revealed
a missense mutation in exon 7 (C1176G; AGC→AGG).
The residue Ser299Arg mutated in patients is at the
center of a coiled, charged region, separating the two
short helices of DSP sub-domain Z. It suppresses a pu-
tative phosphorylation site which is fully conserved in
related proteins belonging to the same family, thus sup-
porting the hypothesis that the amino acid change
might cause a functional alteration. This mutation is
thought to disrupt a protein kinase C (PKC) phosphory-
lation site which is involved in plakoglobin binding and
in clustering of desmosomal cadherin-plakoglobin com-
plexes.
Desmoplakin, together with plakoglobin, anchors to
desmosomal cadherins, forming an ordered array of
non-transmembrane proteins, which then bind to ker-
atin intermediate filaments (IF) (47). The primary struc-
ture of desmoplakin contains three functional domains:
the N-terminal, which binds to the desmosome via con-
nection with plakoglobin and plakophilin; the rod seg-
ment, which is predicted to form a dimeric coil; and the
C-terminal domain, which binds IF’s (48). Alternative
splicing of the protein produces two isoforms, desmo-
plakin I and desmoplakin II. The cDNAs encoding these
two highly related proteins differ in a 1.8 Kbase se-
quence that is missing in DSPII, most likely due to dif-
ferential splicing of a longer transcript (49).
Actually, mutations in desmoplakin gene have been
shown to underlie some cases of an autosomal domi-
nant skin disorder (striate palmoplantar keratoderma)
without cardiac involvement (50-52), a dominant form of
ARVC without skin disease, an autosomal recessive
condition characterized by dilated cardiomyopathy,
woolly hair and keratoderma, named “Carvajal syn-
drome” (53), an autosomal recessive condition charac-
terized by ARVC, woolly hair and keratoderma (27) and
a left-sided ARVC named arrhythmogenic left ventricu-
lar cardiomyopathy (ALVC) (54) (Tab. I).
In 2004, Gerull et al directly sequenced all 14 exons
of the PKP2 gene, including flanking intronic splice se-
quences. These authors identified 25 different heterozy-
gous mutations (12 insertion-deletion, 6 nonsense, 4
missense and 3 splice site mutations) in 32 over 120 un-
related  ARVC  probands  (18).  PKP2  gene  encodes
plakophilin-2,  an  essential  protein  of  the  cardiac
desmosome.
Plakophilin-2 gene was selected as candidate gene
on the basis of the finding of a lethal defect in cardiac
morphogenesis at embryonic day 10.75 in mice ho-
mozygous with respect to a deletion mutation of Pkp2.
The resulting mutant mice exhibit lethal alterations in
heart morphogenesis characterized by reduced trabec-
ulation, disarrayed cytoskeleton, ruptures of cardiac
walls, and blood leakage into the pericardiac cavity. In
the absence of plakophilin-2, the cytoskeletal linker
protein desmoplakin dissociates from the plaques ofRampazzo
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the adhering junctions that connect the cardiomyocytes
and forms granular aggregates in the cytoplasm (55).
Plakophilin-2 is an armadillo-related protein, located
in the outer dense plaque of desmosomes. It links
desmosomal cadherins to desmoplakin and the inter-
mediate filament system. Plakophilins are also present
in the nucleus, where they may play a role in transcrip-
tional regulation (56). Gerull et al speculated that lack of
plakophilin-2 or incorporation of mutant plakophilin-2 
in the cardiac desmosomes might impair cell-cell con-
tacts and, as a consequence, might disrupt association
between adjacent cardiomyocytes, particularly in re-
sponse to mechanical stress or stretch (thus providing a
potential explanation for the high prevalence of the dis-
order in athletes, the frequent occurrence of ventricular
tachyarrhythmias and sudden death during exercise,
and the predominant affection of the right ventricle).
The potential cellular mechanism for the initiation of
ventricular tachyarrhythmias in ARVC could be the 
intrinsic variation in conduction properties as a re-
TABLE I - KNOWN DESMOPLAKIN MUTATIONS AND ASSOCIATED DISEASE
Disease Inheritance Nucleotide Change(s) Amino acid Change(s) References
Striate subtype of  Dominat C1323T Q331X Amstrong et al, 1999
palmoplantar keratoderma
Striate palmoplantar  Dominant 939+1G>A Mutant splice product Whittock et al, 1999
keratoderma
Dilated cardiomyopathy,  Recessive 7901delG Frameshift leading to a  Norgett et al, 2000
woolly hair and keratoderma premature stop codon 
and truncated protein
Skin fragility and woolly  Compound  861T>G and 2427T>A N287K and C809X Whittock et al, 2002
hair syndrome heterozygosity
Skin fragility and woolly  Compound 1990C>T and 7096C>T Q664X and R2366G Whittock et al, 2002
hair syndrome heterozygosity
ARVC Dominant C1176G S299R Rampazzo et al, 2002
ARVC, skin disorder  Recessive G7402C G2375R Alcalai et al, 2003
and woolly hair
Arrhythmogenic left  Dominant 2034insA Frameshift leading to a Normann et al, 2005
ventricular cardiomyopathy  premature stop codon
(ALVC)  and truncated protein   
TABLE II - KNOWN ARVD GENES AND CAUSATIVE MUTATIONS IDENTIFIED SO FAR
ARVD  Gene  Mutations  References 
ARVD1  TGFβ3  2 regulatory mutations (in 5’ e 3’ UTRs) Beffagna et al, 2005
among 33 probands
ARVD2 RYR2 6 mutations (missense) in affected  Tiso et al, 2001; 
subjects belonging to 6 families Bauce et al, 2002;
d’Amati et al, 2005
ARVD8 DSP 4 mutations (3 missense and 1 splice site)  Rampazzo et al, 2002;
in affected subjects belonging to 4 large families Bauce et al, 2005
ARVD9 PKP2 25 mutations (missense, nonsense, insertion/ Gerull et al, 2004
deletion and splicing site) in 32 unrelated patients 
among 120 probands
NAXOS JUP 1 mutation (2bp-deletion) in affected patients  McKoy et al, 2000
belonging to a large familyGenetics of ARVC
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sult of the patchy areas of fibro-fatty cardiomyocyte
degeneration.
Desmosomes  are  important  cell-cell  adhesion
junctions which are predominantly found in the epi-
dermis and heart and which couple cytoskeletal ele-
ments to the plasma membrane at cell-cell or cell-
substrate adhesions. Whereas adherens junctions
associate with microfilaments at cell-cell interfaces,
desmosomes are tailored to anchor stress-bearing
intermediate filaments at sites of strong intercellular
adhesion. The resulting scaffold plays a key role in
providing mechanical integrity to tissues such as
epidermis and heart which experience mechanical
stress. Desmosomes include proteins from at least
three distinct gene families: cadherins, armadillo
proteins and plakins. Desmosomal cadherins in-
clude desmogleins and desmocollins; members of
both subfamilies are single-pass transmembrane
glycoproteins, mediating Ca2+-dependent cell-cell
adhesion. Armadillo proteins include plakoglobin
and plakophilins (PKP1-3). The plakin family pro-
teins include desmoplakin, plectin and the cell enve-
lope proteins envoplakin and periplakin. Since the
desmoplakin  involved  in  ARVD8,  plakophilin  in-
volved in ARVD9 and plakoglobin involved in Naxos
syndrome encodes desmosomal proteins, different
defects in proteins of desmosomal complex lead to
ARVC. Thus, additional components of the desmo-
somal complex become good candidate genes for
ARVC.
More recently, our group succeeded in identifying
the gene involved in ARVD1. In one family fulfilling
diagnostic criteria for ARVC, significant linkage to
ARVD1 was detected, thus confirming the early lo-
cus assignment (57). The critical interval for ARVD1,
still very large, contains 40 known genes; five of
them (POMT2, KIAA0759, KIAA1036, C14orf4 and
TAIL1) were unsuccessfully screened for pathogenic
ARVC mutations (57, 58). Among genes mapped to
ARVD1 critical region and expressed in myocardium,
transforming growth factor-beta3 (TGFβ3) appeared
a very good candidate, as it encodes a cytokine
stimulating fibrosis and modulating cell adhesion
(59). After previous analyses failed to detect any mu-
tation in the coding region of this gene, mutation
screening was extended to the promoter and un-
translated regions (UTRs).
A nucleotide substitution (c.-36G>A) in 5’UTR of
TGFβ3 gene was detected in all affected subjects
belonging to a large ARVD1 family. After the investi-
gation was extended to 30 unrelated ARVC index
patients, an additional mutation (c.1723C>T) was
identified in the 3’ UTR of one proband. In vitro ex-
pression assays of constructs containing the muta-
tions showed that mutated UTRs were twofold more
active than wild-types (19).
TGF-β3 is a member of the transforming growth
factor family. The TGF-β superfamily consist of a di-
verse range of proteins that regulate many different
physiological processes, including embryonic de-
velopment, homeostasis, wound healing, chemo-
taxis, and cell cycle control. Cytokines of the TGF-β
superfamily are dimeric proteins with conserved
structures and have pleiotropic functions in vitro and
in vivo (60).
TGF-β1, -β2, -β3 are the prototypes of the TGF-β
superfamily; they inhibit proliferation in most types
of cells and induce the apoptosis of ephitelial cells.
Conversely, TGF-β1, -β2, -β3 stimulate mesenchy-
mal cells to proliferate and produce extracellular
matrix and induce a fibrotic response in various tis-
sue in vivo. Thus, the TGF-β superfamily regulates
wide-ranging and diverse roles in development, dif-
ferentiation, and homeostasis (60).
Finding TGFβ3 mutations associated with ARVC is
very interesting, as it is well established that TGFβs
stimulate mesenchymal cells to proliferate and to
produce extracellular matrix components. It may be
hypothesized that the reported mutations in UTRs of
TGFβ3 gene, which in vitro enhance expression,
could promote myocardial fibrosis. Extensive my-
ocardial fibrosis may disrupt electrical and mechan-
ical behavior of the myocardium and extracellular
matrix abnormalities may predispose to re-entrant
ventricular arrhythmias (61). In fact, endomyocardial
biopsy in the two probands shows extensive re-
placement-type fibrosis, in agreement with this hy-
pothesis. 
It has been shown that TGFβs modulate expres-
sion of genes encoding desmosomal proteins in dif-
ferent cell types. cDNA microarray analysis per-
formed on RNA from cardiac fibroblasts incubated in
the presence or in the absence of exogenous TGFβs
revealed increased expression of different genes, in-Rampazzo
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cluding plakoglobin (62). Yoshida et al reported that
TGFβ1 exposure of cultured airway epithelial cells
increases the content of desmoplakins I and II; this
suggests that regulation of cell-cell junctional com-
plexes may be an important effect due to TGFβs
(63). Therefore, overexpression of TGFβ3, caused by
UTRs mutations, might affect as well cell-to-cell
junction stability, thus leading to a final outcome
similar to that observed in ARVD8 (17) and in the
ARVC-related Naxos syndrome (15). This would ex-
plain as well the preferential affection of the right
ventricle. 
Known  ARVD  genes  and  causative  mutations
identified so far are reported in Table II.
CONCLUSION
The reported involvement of different desmoso-
mal proteins in ARVCs and the discovery that some
RYR2 mutations may produce ARVD2, lead us to put
forward a novel hypothesis on molecular pathogen-
esis of ARVCs (17). According to such hypothesis,
the almost selective affection of the right ventricle in
ARVCs might be in relation to higher extensibility of
its wall, in comparison with the free wall of left ven-
tricle. 
Possibly, defective proteins in cardiac desmo-
somes  might  impair  cell-to-cell  contacts  and,
hence, might affect the response of ventricular my-
ocardium  to  mechanical  stretch.  This  alteration
would occur preferably in areas subjected to high
strain. These localizations, including the right ven-
tricular outflow tract, the apex and sub-tricuspid ar-
eas, are known as “the triangle of dysplasia”. 
According  to  present  knowledge,  mechanical
forces  applied  to  adherens  junctions  activate
stretch-sensitive calcium channels via cadherins’
mechanical  intracellular  signaling  (64).  Data  on
stretch-activated channels in ventricular cardiomy-
ocytes (65-67) point to the relevance of such chan-
nels in transduction of mechanical forces into a cel-
lular electrochemical signal via increase in intracel-
lular calcium concentration. 
Volume overload in the right ventricle of a person
carrying genetically defective intercellular junctions
(as in case of mutant plakoglobin, desmoplakin or
plakophilin) would produce over-stretch and, hence,
excessive calcium load. Stretching of cardiomy-
ocytes is known to modulate the elementary calcium
release process from ryanodine receptor release
channels (68); therefore, a genetically impaired re-
sponse to mechanical stress might adversely affect
intracellular calcium concentration and the excita-
tion-contraction coupling, producing arrhythmias.
On the other hand, volume overload of the right ven-
tricle in carriers of mutations in RYR2 (cardiac ryan-
odine receptor) would cause calcium overload, be-
cause of the defective Ca++ homeostasis. The exis-
tence of a dominant form of ARVC (ARVD2) due to
RyR2 mutations supports the hypothesis of a key
pathogenic role of intracellular calcium overload in
molecular pathogenesis of ARVDs.
The ongoing progresses of molecular genetics
are leading to new concepts about the pathogenesis
and diagnosis of arrhythmic heart diseases. At the
same time, genetic studies on patients with inherit-
ed diseases are accompanied by the onset of sever-
al medical and ethical problems. An immediate clin-
ical benefit from the discovery of human gene muta-
tions in affected subjects is early and accurate diag-
nosis. However, in some cases, a pathological muta-
tion can exist in the setting of healthy or borderline
phenotype. The detection in apparently healthy sub-
jects of a human gene mutation raises complex clin-
ical management issues.
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